Economic Affairs Director Of Japan’s MHLW Comments On Daiichi Sankyo's Buyout Of Ranbaxy
This article was originally published in PharmAsia News
Commenting on Daiichi Sankyo's buyout of Ranbaxy, Toshihiko Takeda, the economic affairs director of the Ministry of Health, Labor and Welfare's Health Policy Bureau, said he was surprised but thought as a new drug developer, Daiichi Sankyo took a step in the right direction to further expand overseas in a more competitive market. Even though it is still too early to judge how the generics market will develop in Japan, if after the merger Daiichi Sankyo decides to enter the generics market in Japan, it will have credibility as a major drug maker combined with low production costs in India. The legitimacy of the company's generics unit could contribute to the expansion of generic utilization in Japan. (Click here for more - Japanese language) "Economic Affairs Director Toshihiko Takeda Comments on Daiichi Sankyo's Buyout Of Ranbaxy" - Yakuji News (6/11/08)
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.